Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC: Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
NCT06800092Phase 3Not yet recruiting
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Jun 2027
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sildenafil in cognitive impairment, fatigue, sponsored by The University of Texas Medical Branch at Galveston. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
sildenafil
03
Conditions
cognitive impairmentfatigue
Beyond the preview
Go deeper on NCT06800092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800092.